Yinhua CSI Innovative Drugs Industry ETF

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Fosun Pharma: Expected to submit NDA by year-end

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

BeiGene's Brukinsa Approved by FDA

Norges Bank Increases Holding of Tigermed to 813,800 Shares

159892

512290

159837

159992

159316

159859

159849

159570

520500

588130

United Laboratories has received clearance from China's NMPA to begin clinical trials for its innovative drug TUL108, a broad-spectrum beta-lactamase inhibitor aimed at treating bacterial infections. The drug will be tested in combination with meropenem against drug-resistant pathogens. The U.S. FDA had previously approved the investigational new drug application for TUL108 on January 28, 2026.

PUBT

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Tianhong CNI BIOMEDICINE ETF

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Huaan Hang Seng Biotech ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

UNITED LAB

HKEX

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

United Labs says China regulator clears TUL108 injection for clinical trial

01801

516930

516500

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

prnewswire

INNOVENT BIO

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

TransThera Sciences (Nanjing), Inc. is raising HK$156 million through a placement of 3,836,000 new H shares at HK$40.83 each, an 18% discount to market prices. This represents 1.24% of its existing H-share capital and aims to broaden the shareholder base despite modest dilution for current holders. The transaction is subject to regulatory approvals and may not complete, posing execution risks as the company seeks capital for operations and strategic plans.

Tip Ranks

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

TRANSTHERA-B

TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement

09995

688331

RemeGen Co. Ltd. plans to amend its articles of association to increase registered capital and total issued A shares due to its 2022 and 2023 Restricted A Share Incentive Schemes. The company will also update internal governance documents to enhance compliance and internal controls, with changes to be approved at the 2025 annual general meeting. This move aims to align governance with regulatory guidelines and improve oversight of board operations and executive pay.

REMEGEN

RemeGen

Bosera Hang Seng Health Care ETF(QDII)

RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances

02268

WXXWY

02269

ARKG

Earendil Labs has announced the successful dosing of the first cohort in a Phase I clinical trial for HXN-1011, a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP). This antibody shows high affinity and blocks TSLP receptor interactions, demonstrating potent activity in preclinical studies. The company aims to develop innovative treatments for various immunological disorders, emphasizing their commitment to advancing next-generation biologics therapies.

WUXI XDC

WuXi Biologics

WUXI BIO

Sanofi

iShares US Pharma

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

Microbiotica announced positive results from its phase 1b MELODY-1 trial of MB097 for advanced melanoma, meeting all objectives. The trial involved 41 patients and showed MB097's safety and early efficacy when combined with pembrolizumab. The nine-strain bacterial consortium demonstrated robust engraftment, especially with vancomycin preconditioning. The results support further studies in a broader patient population, aiming to enhance responses to anti-PD-1 therapy.

PharmaTimes

BlackRock, Inc.

Proshares UltraShort Nasdaq Biotech

Microbiotica reports positive results for MB097 in advanced melanoma

China's 12th batch of centralized drug procurement will include over 70 varieties and 233 specifications, marking a record high. This batch introduces a pre-filing mechanism for transparency. Major drugs like Entresto, with annual sales of CNY8 billion, face intense competition. The new medical insurance policy limits reimbursements to procurement prices, influencing patient choices towards lower-priced options. The National Healthcare Security Administration plans to enhance procurement rules to foster competition among enterprises.

Yicai

China’s 12th Batch of Centralized Drug Procurement to Cover Record Number of Varieties

Harbour BioMed announced promising preclinical data for LET003, its first AI-enabled drug candidate targeting obesity. LET003 demonstrated superior pharmacokinetics and enhanced fat reduction when combined with semaglutide, while preserving lean mass. The results suggest LET003 could be a best-in-class therapy for obesity, achieving significant fat loss and lean mass improvement at lower doses compared to competitors. The findings were supported by the company's Hu-mAtrIx™ AI platform, indicating strong potential for future development.

HBM HOLDINGS-B

20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

TransThera Sciences (Nanjing) has reported promising results for its multi-kinase inhibitor tinengotinib in advanced solid tumors. In a phase Ib/II study, tinengotinib achieved objective response rates of 16.7% as a monotherapy and 22.6% in combination with atezolizumab, particularly effective in cholangiocarcinoma patients. The drug demonstrated efficacy in FGFR2 fusion cases resistant to prior treatments, supporting further clinical development.

Hwabao WP CSI Pharmaceuticals ETF

TransThera reports promising tinengotinib results in advanced solid tumors

01952

On May 14, 2026, Wei Fu, a substantial shareholder of Everest Medicines, purchased 660,000 shares for approximately HK$20.7 million, marking his second acquisition this year. His previous purchase was on March 27, acquiring 860,000 shares. These actions reflect his confidence in the company's strategic direction and operational achievements, as Everest aims for over RMB15 billion in revenue by 2030. The company reported a 142% revenue increase in 2025, achieving profitability for the first time and strong sales in its innovative drugs.

Asian Corporate Newswire

EVEREST MED

Yinhua CNI HK Connect Innovative Drugs ETF

Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence

Hong Kong stocks' innovative medicine sector surges 66%, three-pronged approach ignites the golden track

WUXI APPTEC

WuXi AppTec

3SBIO

DUALITYBIO-B

HENGRUI PHARMA

Hengrui Pharma

INNOCARE

InnoCare Pharma

AKESO

JOINN

Hong Kong stocks' innovative drugs surge 66%! Three major catalysts ignite the 'golden track', can we still get on board in the second half of the year?

Yinhua CSI Innovative Drugs Industry ETF(159992.SZ)

United Labs says China regulator clears TUL108 injection for clinical trial

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement

RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)